Compare Mattel Inc (MAT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Twist Bioscience Corp — how do they compare? Mattel Inc trades at $16.78 (market cap $4.74B), while Twist Bioscience Corp trades at $161.76 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 2.1× Mattel Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Twist Bioscience Corp for 27 Days on average.
| MAT | TWST | |
|---|---|---|
Market Cap | $4.74B | $10.08B |
Volume | 11,809,722 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $205.00 |
52-Week Low | $12.66 | $25.45 |
Typical Hold Time | 97 Days | 27 Days |
Enterprise Value | $6.96B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $17.12, up 4.58% amid takeover speculation from Authentic Brands Group. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, the company maintains solid profitability with 7.78% net margins and 20.5% ROE, though recent earnings have been mixed with two misses in the last three quarters. Leadership transition is underway with Roger Lynch replacing Ynon Kreiz as CEO.
The takeover interest creates near-term upside potential, but execution risks remain under new leadership. Analyst consensus is bullish with 53% buy ratings and $15 price target, though current price exceeds target. Key risks include Barbie sales deterioration, integration challenges for new CEO, and declining operating cash flow from $870M in 2023 to $593M in 2025.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
